PK11007
Code | Size | Price |
---|
TAR-T7703-1mg | 1mg | £103.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7703-2mg | 2mg | £118.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7703-5mg | 5mg | £148.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7703-10mg | 10mg | £195.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7703-25mg | 25mg | £309.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7703-50mg | 50mg | £438.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7703-100mg | 100mg | £611.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
PK11007 is an anti-p53 drug.
CAS:
874146-69-7
Formula:
C15H11ClFN5O3S2
Molecular Weight:
427.85
Pathway:
Apoptosis; Metabolism; NF-κb; Immunology/Inflammation
Purity:
0.98
SMILES:
Cc1nnc(NC(=O)c2nc(ncc2Cl)S(=O)(=O)Cc2ccc(F)cc2)s1
Target:
Reactive Oxygen Species; p53
References
Duffy M J , Synnott N C , Crown J . Mutant p53 in breast cancer: potential as a therapeutic target and biomarker[J]. Breast Cancer Research and Treatment, 2018.
Synnott N C , Bauer M R , Madden S , et al. Mutant p53 as A Therapeutic Target for the Treatment of Triple-Negative Breast Cancer: Preclinical Investigation with the Anti-p53 Drug, PK11007[J]. Cancer Letters, 2017:S0304383517306225.